Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.
Elderly patients with Clostridium difficile (C. difficile) infection who were given extended-pulsed fidaxomicin were more likely to have sustained clinical cure a month after treatment than those on standard-dose vancomycin, results of the phase 3b/4 EXTEND* trial show.
The risk of Clostridium difficile infection (CDI) in hospitalized patients may be halved by a strategy of administering probiotics within 2 days of antibiotic initiation, according to the results of a systematic review.
Bezlotoxumab, a human monoclonal antibody against Clostridium difficile (C. difficile) toxin B, appears to reduce the risk of recurrent C. difficile infection, according to findings from the MODIFY I* and MODIFY II** trials.
Foecal microbiota transplantation (FMT) done through the lower gastrointestinal (LGI) delivery route appears to be the most effective way for the prevention of recurrence/relapse of Clostridium difficile infection (CDI), suggests a study.
Transfer of sterile filtrates, rather than faecal microbiota, from donor stool may be enough to restore normal stool habits and eliminate symptoms in patients with Clostridium difficile infection (CDI), according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Vancomycin is similarly effective and superior to metronidazole for the treatment of mild and severe Clostridium difficile infections, respectively, as presented in a systematic review and meta-analysis of 17 studies.
There is a multiplicity of causes of acute abdominal pain during childhood although for the purposes of this article those presenting predominantly during the neonatal period will be excluded. Although common sense tells us that most children with acute abdominal pain will have self-limiting conditions, it is important to identify those where there is a more serious surgical or medical emergency. The history of the complaint is the beginning of the diagnostic process and certain conditions are much more common in a particular age group, eg, intussusception. Still, accurate diagnosis can be challenging in the young non-verbal child or those with learning difficulties.
More than half of healthy individuals who volunteered to become a standard donor for faecal microbiota transplantation (FMT) have failed prescreening and have not undergone blood and stool testing, reports a recent study.